Nov 06, 2023 8:23am EST DiaMedica Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update November 14, 2023
Sep 12, 2023 8:13am EDT DiaMedica Therapeutics Announces the Appointment of Ambarish Shah, Ph.D. as Chief Technology Officer
Sep 06, 2023 8:35am EDT DiaMedica Therapeutics to Participate at Lake Street’s 7th Annual Best Ideas Growth Conference
Aug 14, 2023 4:13pm EDT DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2023 Financial Results
Aug 08, 2023 8:32am EDT DiaMedica Therapeutics to Report Second Quarter 2023 Financial Results and Provide a Business Update August 15, 2023
Jul 18, 2023 8:30am EDT DiaMedica Therapeutics to Attend the American Academy of Neurology Summer Conference
Jun 21, 2023 8:15am EDT DiaMedica Therapeutics Announces that the FDA Has Removed The Clinical Hold On DM199 Phase 2/3 Trial For Ischemic Stroke
May 30, 2023 8:29am EDT DiaMedica Therapeutics Announces Appointment of Dr. Richard Kuntz to the Board of Directors
